Cost-Effective HIV PrEP: CAB-LA Transforms Prev...

By Rene Pretorius

April 16, 2025

Summary Cabotegravir long-acting (CAB-LA) delivers a cost-effective HIV PrEP solution. It reduces infections and supports the Ending the HIV Epidemic (EHE) initiative. This review exami...
Global Health Limitations: A Critical Assessment of Structural Constraints an...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Balancing Pandemic Preparedness Priorities and Military Spending
Reassuring the Private Sector on National Health Insurance South Africa: A Pa...
Exploring the MASLD CKD Socioeconomic Link
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
South Africa Cannabis Regulations: Government Withdraws Ban for New Framework...
Addressing Cancer Care Disparities in Europe: Insights from the 2025 Comparat...
Global Initiative Launches Access to Essential Childhood Cancer Medicines
Enhancing Colorectal Cancer Screening Through Mail and Navigation Strategies
NovoCare and the Rise of Direct-to-Consumer Pharmaceutical Access
ACS Management Innovations: Transforming Patient Outcomes in Acute Coronary S...